Search

Your search keyword '"Rheingold, Susan R."' showing total 498 results
Start Over Author "Rheingold, Susan R."
498 results on '"Rheingold, Susan R."'

1. Determinants of survival after first relapse of acute lymphoblastic leukemia: a Children’s Oncology Group study

Author

Rheingold, Susan R., Bhojwani, Deepa, Ji, Lingyun, Xu, Xinxin, Devidas, Meenakshi, Kairalla, John A., Shago, Mary, Heerema, Nyla A., Carroll, Andrew J., Breidenbach, Heather, Borowitz, Michael, Wood, Brent L., Angiolillo, Anne L., Asselin, Barbara L., Bowman, W. Paul, Brown, Patrick, Dreyer, ZoAnn E., Dunsmore, Kimberly P., Hilden, Joanne M., Larsen, Eric, Maloney, Kelly, Matloub, Yousif, Mattano, Leonard A., Winter, Stuart S., Gore, Lia, Winick, Naomi J., Carroll, William L., Hunger, Stephen P., Raetz, Elizabeth A., and Loh, Mignon L.

Published
2024
Full Text
View/download PDF

3. Reinfusion of CD19 CAR T cells for relapse prevention and treatment in children with acute lymphoblastic leukemia

Author

Myers, Regina M., Devine, Kaitlin, Li, Yimei, Lawrence, Sophie, Leahy, Allison Barz, Liu, Hongyan, Vernau, Lauren, Callahan, Colleen, Baniewicz, Diane, Kadauke, Stephan, McGuire, Regina, Wertheim, Gerald B., Kulikovskaya, Irina, Gonzalez, Vanessa E., Fraietta, Joseph A., DiNofia, Amanda M., Hunger, Stephen P., Rheingold, Susan R., Aplenc, Richard, June, Carl H., Grupp, Stephan A., Wray, Lisa, and Maude, Shannon L.

Published
2024
Full Text
View/download PDF

5. Outcomes after late bone marrow and very early central nervous system relapse of childhood B-acute lymphoblastic leukemia: a report from the Children's Oncology Group phase III study AALL0433

Author

Lew, Glen, Chen, Yichen, Lu, Xiaomin, Rheingold, Susan R, Whitlock, James A, Devidas, Meenakshi, Hastings, Caroline A, Winick, Naomi J, Carroll, William L, Wood, Brent L, Borowitz, Michael J, Pulsipher, Michael A, and Hunger, Stephen P

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Oncology and Carcinogenesis, Clinical Trials and Supportive Activities, Clinical Research, Hematology, Transplantation, Pediatric Cancer, Childhood Leukemia, Pediatric Research Initiative, Rare Diseases, Orphan Drug, Cancer, Pediatric, 6.1 Pharmaceuticals, 4.2 Evaluation of markers and technologies, Evaluation of treatments and therapeutic interventions, Detection, screening and diagnosis, Good Health and Well Being, Bone Marrow, Central Nervous System, Child, Disease-Free Survival, Humans, Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Prognosis, Recurrence, Treatment Outcome, Cardiorespiratory Medicine and Haematology, Immunology, Cardiovascular medicine and haematology
Abstract

Outcomes after relapse of childhood B-acute lymphoblastic leukemia (B-ALL) are poor, and optimal therapy is unclear. Children's Oncology Group study AALL0433 evaluated a new platform for relapsed ALL. Between March 2007 and October 2013 AALL0433 enrolled 275 participants with late bone marrow or very early isolated central nervous system (iCNS) relapse of childhood B-ALL. Patients were randomized to receive standard versus intensive vincristine dosing; this randomization closed due to excess peripheral neuropathy in 2010. Patients with matched sibling donors received allogeneic hematopoietic cell transplantation (HCT) after the first three blocks of therapy. The prognostic value of minimal residual disease (MRD) was also evaluated in this study. The 3-year event free and overall survival (EFS/OS) for the 271 eligible patients were 63.6% +/- 3.0% and 72.3% +/- 2.8% respectively. MRD at the end of Induction-1 was highly predictive of outcome, with 3-year EFS/OS of 84.9 +/- 4.0% and 93.8 +/- 2.7% for patients with MRD

Published
2021

6. Outcome of chimeric antigen receptor T-cell therapy following treatment with inotuzumab ozogamicin in children with relapsed or refractory acute lymphoblastic leukemia

Author

Ceolin, Valeria, Brivio, Erica, van Tinteren, Harm, Rheingold, Susan R., Leahy, Allison, Vormoor, Britta, O’Brien, Maureen M., Rubinstein, Jeremy D., Kalwak, Krzysztof, De Moerloose, Barbara, Jacoby, Elad, Bader, Peter, López-Duarte, Mónica, Goemans, Bianca F., Locatelli, Franco, Hoogerbrugge, Peter, Calkoen, Friso G., and Zwaan, Christian Michel

Published
2023
Full Text
View/download PDF

7. Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells

Author

Lamble, Adam J., Myers, Regina M., Taraseviciute, Agne, John, Samuel, Yates, Bonnie, Steinberg, Seth M., Sheppard, Jennifer, Kovach, Alexandra E., Wood, Brent, Borowitz, Michael J., Stetler-Stevenson, Maryalice, Yuan, Constance M., Pillai, Vinodh, Foley, Toni, Chung, Perry, Chen, Lee, Lee, Daniel W., Annesley, Colleen, DiNofia, Amanda, Grupp, Stephan A., Verneris, Michael R., Gore, Lia, Laetsch, Theodore W., Bhojwani, Deepa, Brown, Patrick A., Pulsipher, Michael A., Rheingold, Susan R., Gardner, Rebecca A., and Shah, Nirali N.

Published
2023
Full Text
View/download PDF

8. Impact of poverty and neighborhood opportunity on outcomes for children treated with CD19-directed CAR T-cell therapy

Author

Newman, Haley, Li, Yimei, Liu, Hongyan, Myers, Regina M., Tam, Vicky, DiNofia, Amanda, Wray, Lisa, Rheingold, Susan R., Callahan, Colleen, White, Claire, Baniewicz, Diane, Winestone, Lena E., Kadauke, Stephan, Diorio, Caroline, June, Carl H., Getz, Kelly D., Aplenc, Richard, Teachey, David T., Maude, Shannon L., Grupp, Stephan A., Bona, Kira, and Leahy, Allison Barz

Published
2023
Full Text
View/download PDF

9. Correction: Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia

Author

Bhojwani, Deepa, Sposto, Richard, Shah, Nirali N, Rodriguez, Vilmarie, Yuan, Constance, Stetler-Stevenson, Maryalice, O’Brien, Maureen M, McNeer, Jennifer L, Quereshi, Amrana, Cabannes, Aurelie, Schlegel, Paul, Rossig, Claudia, Dalla-Pozza, Luciano, August, Keith, Alexander, Sarah, Bourquin, Jean-Pierre, Zwaan, Michel, Raetz, Elizabeth A, Loh, Mignon L, and Rheingold, Susan R

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Clinical Sciences, Oncology and Carcinogenesis, Cancer, Rare Diseases, Pediatric Cancer, Pediatric, Good Health and Well Being, Immunology, Cardiovascular medicine and haematology, Clinical sciences, Oncology and carcinogenesis
Abstract

We thank the research coordinators and following physicians at pediatric cancer centers for contributing data to this project: Prashant Hiwarkar and Jayashree Motwani, Birmingham Women's and Children's Hospital, UK; Kelly Malone, Children's Hospital of Colorado, USA; Mylene Bassal, Children's Hospital of Eastern Ontario, Canada; Yoav Messinger and Joanna Perkins, Children's Hospital of Minnesota, USA; Van Huynh, Children's Hospital of Orange County, USA; Richard Ho, Children's Hospital at Vanderbilt, USA; Joanne Chuah and Jessa Morales, Children's Hospital at Westmead, Australia; Donald Wells, Dell Children's Hospital, USA; Nicolas Boissel, Hospital Saint-Louis, France; Tannie Huang, Kaiser Permanente, USA; Stacey Marjerrison, McMaster Children's Hospital, Canada; William Carroll and Joanna Pierro, New York University Langone Medical Center, USA; Ajay Vora, Sheffield Children's Hospital, UK; Donna Lancaster, The Royal Marsden Hospital, UK; Lucie Šrámková, University Hospital Motol, Czech Republic; Chatchawin Assanasen, University of Texas Health Science Center, San Antonio, USA; Rupert Handgretinger, University of Tübingen, Germany.

Published
2019

10. Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia

Author

Bhojwani, Deepa, Sposto, Richard, Shah, Nirali N, Rodriguez, Vilmarie, Yuan, Constance, Stetler-Stevenson, Maryalice, O’Brien, Maureen M, McNeer, Jennifer L, Quereshi, Amrana, Cabannes, Aurelie, Schlegel, Paul, Rossig, Claudia, Dalla-Pozza, Luciano, August, Keith, Alexander, Sarah, Bourquin, Jean-Pierre, Zwaan, Michel, Raetz, Elizabeth A, Loh, Mignon L, and Rheingold, Susan R

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Oncology and Carcinogenesis, Pediatric Research Initiative, Childhood Leukemia, Rare Diseases, Stem Cell Research, Cancer, Pediatric, Hematology, Transplantation, Clinical Research, Pediatric Cancer, Adolescent, Adult, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Child, Child, Preschool, Drug Resistance, Neoplasm, Female, Humans, Inotuzumab Ozogamicin, Male, Neoplasm Recurrence, Local, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Prognosis, Remission Induction, Retrospective Studies, Salvage Therapy, Survival Rate, Young Adult, Clinical Sciences, Immunology, Cardiovascular medicine and haematology, Clinical sciences, Oncology and carcinogenesis
Abstract

Although inotuzumab ozogamicin (InO) is recognized as an effective agent in relapsed acute lymphoblastic leukemia (ALL) in adults, data on safety and efficacy in pediatric patients are scarce. We report the use of InO in 51 children with relapsed/refractory ALL treated in the compassionate use program. In this heavily pretreated cohort, complete remission was achieved in 67% of patients with overt marrow disease. The majority (71%) of responders were negative for minimal residual disease. Responses were observed irrespective of cytogenetic subtype or number or type of prior treatment regimens. InO was well-tolerated; grade 3 hepatic transaminitis or hyperbilirubinemia were noted in 6 (12%) and grade 3/4 infections in 11 (22%) patients. No patient developed sinusoidal obstruction syndrome (SOS) during InO therapy; however, 11 of 21 (52%) patients who underwent hematopoietic stem cell transplantation (HSCT) following InO developed SOS. Downregulation of surface CD22 was detected as a possible escape mechanism in three patients who developed a subsequent relapse after InO. We conclude that InO is a well-tolerated, effective therapy for children with relapsed ALL and prospective studies are warranted. Identification of risk factors for developing post-HSCT SOS and strategies to mitigate this risk are ongoing.

Published
2019

12. Outcome of children with multiply relapsed B-cell acute lymphoblastic leukemia: a therapeutic advances in childhood leukemia & lymphoma study

Author

Sun, Weili, Malvar, Jemily, Sposto, Richard, Verma, Anupam, Wilkes, Jennifer J, Dennis, Robyn, Heym, Kenneth, Laetsch, Theodore W, Widener, Melissa, Rheingold, Susan R, Oesterheld, Javier, Hijiya, Nobuko, Sulis, Maria Luisa, Huynh, Van, Place, Andrew E, Bittencourt, Henrique, Hutchinson, Raymond, Messinger, Yoav, Chang, Bill, Matloub, Yousif, Ziegler, David S, Gardner, Rebecca, Cooper, Todd, Ceppi, Francesco, Hermiston, Michelle, Dalla-Pozza, Luciano, Schultz, Kirk R, Gaynon, Paul, Wayne, Alan S, and Whitlock, James A

Subjects
Childhood Leukemia, Pediatric Research Initiative, Hematology, Orphan Drug, Pediatric, Clinical Research, Rare Diseases, Cancer, Pediatric Cancer, Antineoplastic Agents, B-Lymphocytes, Bone Marrow, Child, Child, Preschool, Disease-Free Survival, Female, Humans, Infant, Male, Neoplasm Recurrence, Local, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Remission Induction, Retrospective Studies, Salvage Therapy, Clinical Sciences, Oncology and Carcinogenesis, Immunology
Abstract

The survival of pediatric patients with multiply relapsed and/or refractory (R/R) B-cell acute lymphoblastic leukemia has historically been very poor; however, data are limited in the current era. We conducted a retrospective study to determine the outcome of multiply R/R childhood B-ALL treated at 24 TACL institutions between 2005 and 2013. Patient information, treatment, and response were collected. Prognostic factors influencing the complete remission (CR) rate and event-free survival (EFS) were analyzed. The analytic set included 578 salvage treatment attempts among 325 patients. CR rates (mean ± SE) were 51 ± 4% for patients with bone marrow R/R B-ALL who underwent a second salvage attempt, 37 ± 6% for a third attempt, and 31 ± 6% for the fourth through eighth attempts combined. For patients achieving a CR after their second, third, and fourth through eighth attempts, the 2 year EFS was 41 ± 6%, 13 ± 7%, and 27 ± 13% respectively. Our results showed slight improvement when compared to previous studies. This is the largest and most recent study to date that evaluates the outcome of this patient population. Our data will provide detailed reference for the evaluation of new agents being developed for childhood B-ALL.

Published
2018

18. List of Contributors

Author

Adler, Adam C., primary, Ambardekar, Aditee P., additional, Balamuth, Naomi, additional, Berman, Alexandra, additional, Bhalla, Tarun, additional, Boyer, Donald L., additional, Costandi, Andrew J., additional, Daigle, C. Hunter, additional, Dodson, Gregory, additional, Feldman, Jeffrey M., additional, Fiadjoe, John E., additional, Foster, Jessica, additional, Gallagher, Susan, additional, Jay Garcia, F., additional, Girard, Thierry, additional, Grivoyannis, Anastasia D., additional, Gurnaney, Harshad, additional, Habib, Fatimah, additional, Hsu, Grace, additional, Hunter, Samuel, additional, Isserman, Rebecca S., additional, Jones, Jeremy, additional, Jemma Kang, Ji Yeon, additional, King, Michael R., additional, Wickam Kraemer, F., additional, E. Linder, Grace, additional, Litman, Ronald S., additional, Loh, Katherine H., additional, Mamula, Petar, additional, Garcia-Marcinikiewicz, Annery, additional, Maxwell, Lynne G., additional, Muhly, Wallis T., additional, Nelson, Olivia, additional, Nookala, Asha, additional, Olbrecht, Vanessa A., additional, Patel, Shikha, additional, Perate, Alison, additional, Petrini, Laura A., additional, Pinyavat, Teeda, additional, Renuart, Andrew, additional, Rheingold, Susan R., additional, Rosenblatt, Samuel, additional, Rosenbloom, Julia, additional, Ryan, William, additional, Sesok-Pizzini, Deborah Ann, additional, Setiawan, Christopher, additional, Simpao, Allan F., additional, Stricker, Paul A., additional, Weintraub, Ari Y., additional, Witmer, Char M., additional, Zaoutis, Theoklis, additional, and Zur, Karen B., additional

Published
2022
Full Text
View/download PDF

19. List of contributors

Author

Abdel-Azim, Hisham, primary, Acharya, Suchitra S., additional, Agrawal, Anurag K., additional, Al-Ghafry, Maha, additional, Allen, Carl E., additional, Amin, Seema, additional, Atlas, Mark P., additional, Bagatell, Rochelle, additional, Blanc, Lionel, additional, Blei, Francine, additional, Bussel, James B., additional, Carroll, William L., additional, Connelly, James A., additional, Dome, Jeffrey S., additional, Dulmovits, Brian M., additional, Eckstein, Olive S., additional, Elgarten, Caitlin W., additional, Elghetany, Mohamed Tarek, additional, Federman, Noah, additional, Fein Levy, Carolyn, additional, Feusner, James, additional, Fish, Jonathan D., additional, Fonseca, Adriana, additional, Freedman, Jason L., additional, Friedman, Debra L., additional, Hanson, Derek, additional, Hijiya, Nobuko, additional, Hofmann, Inga, additional, Huang, Mary S., additional, Iacobas, Ionela, additional, Josephson, Cassandra D., additional, Kessel, Rachel, additional, Khandros, Eugene, additional, Krystal, Julie, additional, Kwiatkowski, Janet L., additional, Lanzkowsky, Philip, additional, Leahey, Ann, additional, Lipton, Jeffrey M., additional, McGuinn, Catherine, additional, Mody, Rajen J., additional, Nadel, Amy, additional, Nash, Michelle, additional, Niss, Omar, additional, Olson, Thomas A., additional, Pillai, Pallavi M., additional, Powers, Jacquelyn M., additional, Prchal, Josef T., additional, Pulsipher, Michael A., additional, Quinn, Charles T., additional, Radinsky, Miriam, additional, Redner, Arlene, additional, Rheingold, Susan R., additional, Sarangi, Susmita N., additional, Shah, Amish, additional, Shavit, Jordan A., additional, Smith, Christine M., additional, Sokol, Elizabeth, additional, Sutton, Kathryn S., additional, Tashi, Tsewang, additional, Teachey, David T., additional, Vagrecha, Anshul, additional, Vlachos, Adrianna, additional, Walkovich, Kelly, additional, Warwick, Anne B., additional, Weinstein, Howard J., additional, Winsnes, Katrina, additional, and Wolfe, Lawrence C., additional

Published
2022
Full Text
View/download PDF

20. Optimizing early phase clinical trial washout periods: a report from the Therapeutic Advances in Childhood Leukemia and Lymphoma consortium.

Author

Schafer, Eric S, Rushing, Teresa, Crews, Kristine R, Annesley, Colleen, Colace, Susan I, Kaiser, Nicole, Pommert, Lauren, Ramsey, Laura B, Sabnis, Himalee S, Wong, Kenneth, Chang, Bill H, Cooper, Todd M, Shah, Nirali N, Rheingold, Susan R, Place, Andrew E, Chi, Yueh-Yun, Bhojwani, Deepa, Wayne, Alan S, and Bernhardt, M Brooke

Subjects
COMPREHENSION testing, EMPLOYMENT portfolios, CONSORTIA, TASK forces, LANGUAGE policy
Abstract

Background The National Cancer Institute (NCI) issued a 2021 memorandum adopting the American Society of Clinical Oncology (ASCO) and Friends of Cancer Research (Friends) task force recommendations to broaden clinical study eligibility criteria. They recommended that washout periods be eliminated for most prior cancer therapy and when required to utilize evidence- and/or rationale-based criteria. The Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) consortium responded to this guidance. Methods A TACL task force reviewed the consortium's research portfolio, the relevant literature and guidance documents from ASCO-Friends, NCI, and US Food and Drug Administration to make expert consensus and evidence-based recommendations for modernizing, broadening, and codifying TACL-study washout periods while ensuring consistency with pediatric ethics, and federal regulations. TACL's screening log was reviewed to estimate the impact that updated washout periods would have on patient inclusivity and recruitment. Results Over a 19-year period, 42 (14.6% of all screened ineligible patients [n = 287]) patients were identified as excluded from TACL early phase studies exclusively because of not meeting washout criteria. An additional 6 (2.1%) did not meet washout and at least 1 other exclusion criterion. A new TACL washout guidance document was developed and then adopted for use. Where washout criteria were not eliminated, rationale- and/or evidenced-based criteria were established with citation. Conclusion In an effort to reduce unnecessary exclusion from clinical trials, TACL created rationale- and/or evidenced-based washout period standards largely following guidance from the NCI and ASCO-Friends recommendations. These new, expanded eligibility criteria are expected to increase access to TACL clinical trials while maintaining safety and scientific excellence. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

22. CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy

Author

Pillai, Vinodh, Muralidharan, Kavitha, Meng, Wenzhao, Bagashev, Asen, Oldridge, Derek A., Rosenthal, Jaclyn, Van Arnam, John, Melenhorst, Jos J., Mohan, Diwakar, DiNofia, Amanda M., Luo, Minjie, Cherian, Sindhu, Fromm, Jonathan R., Wertheim, Gerald, Thomas-Tikhonenko, Andrei, Paessler, Michele, June, Carl H., Luning Prak, Eline T., Bhoj, Vijay G., Grupp, Stephan A., Maude, Shannon L., and Rheingold, Susan R.

Published
2019
Full Text
View/download PDF

23. Characterization of Extramedullary Disease (EMD) Response to CD19 Targeted Chimeric Antigen Receptor T-Cells (CART) in Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (B-ALL): A Multi-Site, Retrospective Cohort Review

Author

Rankin, Alexander W., primary, Myers, Regina M., additional, Lamble, Adam, additional, Hsieh, Emily M., additional, Silbert, Sara, additional, Steinberg, Seth M., additional, Annesley, Colleen, additional, Yates, Bonnie, additional, John, Samuel, additional, Sheppard, Jennifer, additional, Chen, Lee, additional, Lee, Daniel W., additional, DiNofia, Amanda, additional, Grupp, Stephan A., additional, Gore, Lia, additional, Pulsipher, Mike A., additional, Shah, Nirali N., additional, Bhojwani, Deepa, additional, Gardner, Rebecca, additional, and Rheingold, Susan R., additional

Published
2024
Full Text
View/download PDF

25. Outcomes in Children, Adolescents, and Young Adults With Down Syndrome and ALL: A Report From the Children's Oncology Group

Author

Rabin, Karen R., primary, Devidas, Meenakshi, additional, Chen, Zhiguo, additional, Ji, Lingyun, additional, Kairalla, John, additional, Hitzler, Johann K., additional, Yang, Jun J., additional, Carroll, Andrew J., additional, Heerema, Nyla A., additional, Borowitz, Michael J., additional, Wood, Brent L., additional, Roberts, Kathryn G., additional, Mullighan, Charles G., additional, Harvey, Richard C., additional, Chen, I-Ming, additional, Willman, Cheryl L., additional, Reshmi, Shalini C., additional, Gastier-Foster, Julie M., additional, Bhojwani, Deepa, additional, Rheingold, Susan R., additional, Maloney, Kelly W., additional, Mattano, Leonard A., additional, Larsen, Eric C., additional, Schore, Reuven J., additional, Burke, Michael J., additional, Salzer, Wanda L., additional, Winick, Naomi J., additional, Carroll, William L., additional, Raetz, Elizabeth A., additional, Loh, Mignon L., additional, Hunger, Stephen P., additional, and Angiolillo, Anne L., additional

Published
2023
Full Text
View/download PDF

26. INSPIRED Symposium Part 4A: Access to CAR T cell Therapy in Unique Populations with B-cell Acute Lymphoblastic Leukemia

Author

Winestone, Lena E., primary, Bhojwani, Deepa, additional, Ghorashian, Sara, additional, Muffly, Lori, additional, Leahy, Allison Barz, additional, Chao, Karen, additional, Steineck, Angela, additional, Rossig, Claudia, additional, Lamble, Adam, additional, Maude, Shannon L., additional, Myers, Regina, additional, and Rheingold, Susan R., additional

Published
2023
Full Text
View/download PDF

29. Outcomes in Children, Adolescents, and Young Adults With Down Syndrome and ALL: A Report From the Children's Oncology Group.

Author

Rabin, Karen R., Devidas, Meenakshi, Chen, Zhiguo, Ji, Lingyun, Kairalla, John, Hitzler, Johann K., Yang, Jun J., Carroll, Andrew J., Heerema, Nyla A., Borowitz, Michael J., Wood, Brent L., Roberts, Kathryn G., Mullighan, Charles G., Harvey, Richard C., Chen, I-Ming, Willman, Cheryl L., Reshmi, Shalini C., Gastier-Foster, Julie M., Bhojwani, Deepa, and Rheingold, Susan R.

Published
2024
Full Text
View/download PDF

30. Data from Modulation of CD22 Protein Expression in Childhood Leukemia by Pervasive Splicing Aberrations: Implications for CD22-Directed Immunotherapies

Author

Zheng, Sisi, primary, Gillespie, Elisabeth, primary, Naqvi, Ammar S., primary, Hayer, Katharina E., primary, Ang, Zhiwei, primary, Torres-Diz, Manuel, primary, Quesnel-Vallières, Mathieu, primary, Hottman, David A., primary, Bagashev, Asen, primary, Chukinas, John, primary, Schmidt, Carolin, primary, Asnani, Mukta, primary, Shraim, Rawan, primary, Taylor, Deanne M., primary, Rheingold, Susan R., primary, O'Brien, Maureen M., primary, Singh, Nathan, primary, Lynch, Kristen W., primary, Ruella, Marco, primary, Barash, Yoseph, primary, Tasian, Sarah K., primary, and Thomas-Tikhonenko, Andrei, primary

Published
2023
Full Text
View/download PDF

31. Supplementary Data from Modulation of CD22 Protein Expression in Childhood Leukemia by Pervasive Splicing Aberrations: Implications for CD22-Directed Immunotherapies

Author

Zheng, Sisi, primary, Gillespie, Elisabeth, primary, Naqvi, Ammar S., primary, Hayer, Katharina E., primary, Ang, Zhiwei, primary, Torres-Diz, Manuel, primary, Quesnel-Vallières, Mathieu, primary, Hottman, David A., primary, Bagashev, Asen, primary, Chukinas, John, primary, Schmidt, Carolin, primary, Asnani, Mukta, primary, Shraim, Rawan, primary, Taylor, Deanne M., primary, Rheingold, Susan R., primary, O'Brien, Maureen M., primary, Singh, Nathan, primary, Lynch, Kristen W., primary, Ruella, Marco, primary, Barash, Yoseph, primary, Tasian, Sarah K., primary, and Thomas-Tikhonenko, Andrei, primary

Published
2023
Full Text
View/download PDF

32. Data from Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia

Author

Teachey, David T., primary, Lacey, Simon F., primary, Shaw, Pamela A., primary, Melenhorst, J. Joseph, primary, Maude, Shannon L., primary, Frey, Noelle, primary, Pequignot, Edward, primary, Gonzalez, Vanessa E., primary, Chen, Fang, primary, Finklestein, Jeffrey, primary, Barrett, David M., primary, Weiss, Scott L., primary, Fitzgerald, Julie C., primary, Berg, Robert A., primary, Aplenc, Richard, primary, Callahan, Colleen, primary, Rheingold, Susan R., primary, Zheng, Zhaohui, primary, Rose-John, Stefan, primary, White, Jason C., primary, Nazimuddin, Farzana, primary, Wertheim, Gerald, primary, Levine, Bruce L., primary, June, Carl H., primary, Porter, David L., primary, and Grupp, Stephan A., primary

Published
2023
Full Text
View/download PDF

33. Supplementary Methods, Tables 1 - 19, Figures 1 - 5 from Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia

Author

Teachey, David T., primary, Lacey, Simon F., primary, Shaw, Pamela A., primary, Melenhorst, J. Joseph, primary, Maude, Shannon L., primary, Frey, Noelle, primary, Pequignot, Edward, primary, Gonzalez, Vanessa E., primary, Chen, Fang, primary, Finklestein, Jeffrey, primary, Barrett, David M., primary, Weiss, Scott L., primary, Fitzgerald, Julie C., primary, Berg, Robert A., primary, Aplenc, Richard, primary, Callahan, Colleen, primary, Rheingold, Susan R., primary, Zheng, Zhaohui, primary, Rose-John, Stefan, primary, White, Jason C., primary, Nazimuddin, Farzana, primary, Wertheim, Gerald, primary, Levine, Bruce L., primary, June, Carl H., primary, Porter, David L., primary, and Grupp, Stephan A., primary

Published
2023
Full Text
View/download PDF

34. Co-Occurrence of Pallister-Killian Syndrome and Burkitt Lymphoma in a Patient with Near-Normal Neurocognitive Development

Author

Izumi, Kosuke, primary, Ganetzky, Rebecca D., additional, Wertheim, Gerald B.W., additional, Skraban, Cara M., additional, Bedoukian, Emma C., additional, Wilkens, Alisha, additional, Fincher, Christopher, additional, Thomas, Nina H., additional, Ginsberg, Jill P., additional, Rheingold, Susan R., additional, Conlin, Laura K., additional, and Deardorff, Matthew A., additional

Published
2023
Full Text
View/download PDF

36. CD22-Targeted CAR-Modified T-Cells Safely Induce Remissions in Children and Young Adults with Relapsed, CD19-Negative B-ALL after Treatment with CD19-Targeted CAR T-Cells

Author

Myers, Regina M., primary, DiNofia, Amanda M., additional, Li, Yimei, additional, Diorio, Caroline, additional, Aplenc, Richard, additional, Baniewicz, Diane, additional, Brogdon, Jennifer L, additional, Callahan, Colleen, additional, Engels, Boris, additional, Fraietta, Joseph A., additional, Gonzalez, Vanessa, additional, Iannone, Emma, additional, Leahy, Allison Barz, additional, Liu, Hongyan, additional, McClory, Susan E., additional, Rheingold, Susan R., additional, Shinehouse, Laura, additional, Wertheim, Gerald, additional, Wray, Lisa, additional, Frey, Noelle V., additional, Maude, Shannon L., additional, and Grupp, Stephan A., additional

Published
2022
Full Text
View/download PDF

37. Outcome of chimeric antigen receptor T-cell therapy following treatment with inotuzumab ozogamicin in children with relapsed or refractory acute lymphoblastic leukemia

Author

Ceolin, Valeria, primary, Brivio, Erica, additional, van Tinteren, Harm, additional, Rheingold, Susan R., additional, Leahy, Allison, additional, Vormoor, Britta, additional, O’Brien, Maureen M., additional, Rubinstein, Jeremy D., additional, Kalwak, Krzysztof, additional, De Moerloose, Barbara, additional, Jacoby, Elad, additional, Bader, Peter, additional, López-Duarte, Mónica, additional, Goemans, Bianca F., additional, Locatelli, Franco, additional, Hoogerbrugge, Peter, additional, Calkoen, Friso G., additional, and Zwaan, Christian Michel, additional

Published
2022
Full Text
View/download PDF

38. Improving infectious adverse event reporting for children and adolescents enrolled in clinical trials for acute lymphoblastic leukemia: A report from the Children's Oncology Group

Author

Elgarten, Caitlin W., primary, Thompson, Joel C., additional, Angiolillo, Anne, additional, Chen, Zhiguo, additional, Conway, Susan, additional, Devidas, Meenakshi, additional, Gupta, Sumit, additional, Kairalla, John A., additional, McNeer, Jennifer L., additional, O'Brien, Maureen M., additional, Rabin, Karen R., additional, Rau, Rachel E., additional, Rheingold, Susan R., additional, Wang, Cindy, additional, Wood, Charlotte, additional, Raetz, Elizabeth A., additional, Loh, Mignon L., additional, Alexander, Sarah, additional, and Miller, Tamara P., additional

Published
2022
Full Text
View/download PDF

39. Low rate of subsequent malignant neoplasms after CD19 CAR T-cell therapy

Author

Hsieh, Emily M., primary, Myers, Regina M., additional, Yates, Bonnie, additional, Annesley, Colleen, additional, John, Samuel, additional, Taraseviciute, Agne, additional, Steinberg, Seth M., additional, Sheppard, Jennifer, additional, Chung, Perry, additional, Chen, Lee, additional, Lee, Daniel W., additional, DiNofia, Amanda, additional, Grupp, Stephan A., additional, Verneris, Michael R., additional, Laetsch, Theodore W., additional, Bhojwani, Deepa, additional, Brown, Patrick A., additional, Pulsipher, Michael A., additional, Rheingold, Susan R., additional, Gardner, Rebecca A., additional, Gore, Lia, additional, Shah, Nirali N., additional, and Lamble, Adam J., additional

Published
2022
Full Text
View/download PDF

40. Abstract 6248: Modulation of CD22 protein expression in childhood leukemia by pervasive splicing aberrations: Implications for CD22-directed immunotherapies

Author

Zheng, Sisi, primary, Gillespie, Elisabeth, additional, Naqvi, Ammar S., additional, Hayer, Katharina E., additional, Ang, Zhiwei, additional, Torres-Diz, Manuel, additional, Quesnel-Vallières, Mathieu, additional, Hottman, David A., additional, Bagashev, Asen, additional, Chukinas, John A., additional, Schmidt, Carolin, additional, Asnani, Mukta Mukta, additional, Shraim, Rawan, additional, Taylor, Deanne M., additional, Rheingold, Susan R., additional, M. O’Brien, Maureen, additional, Singh, Nathan, additional, Lynch, Kristen W., additional, Ruella, Marco, additional, Barash, Yoseph, additional, Tasian, Sarah K., additional, and Thomas-Tikhonenko, Andrei, additional

Published
2022
Full Text
View/download PDF

41. Impact of socioeconomic status on survival after CD19 CART therapy.

Author

Newman, Haley, primary, Li, Yimei, additional, Liu, Hongyan, additional, Tam, Vicky, additional, Myers, Regina M, additional, DiNofia, Amanda M, additional, Callahan, Colleen, additional, White, Claire M, additional, Baniewicz, Diane, additional, Kadauke, Stephan, additional, Diorio, Caroline, additional, Teachey, David T., additional, Rheingold, Susan R., additional, Getz, Kelly D., additional, June, Carl H., additional, Aplenc, Richard, additional, Maude, Shannon L., additional, Grupp, Stephan A., additional, Bona, Kira, additional, and Barz Leahy, Allison Emily, additional

Published
2022
Full Text
View/download PDF

42. Coronavirus Disease 2019 mRNA Vaccination Appears Safe in Pediatric Patients With Hypersensitivity to Polyethylene Glycolated Escherichia coliL-asparaginase

Author

Wolfset, Nicole, Pashmineh Azar, Amir Reza, Phillips, Charles A., Stein, Madison, Rheingold, Susan R., Heimall, Jennifer, and Elgarten, Caitlin W.

Abstract

Polyethylene glycol–asparaginase (PEGAsp) is an established component of acute leukemia therapy. Hypersensitivity reactions to PEGAsp occur in 10% to 15% of patients, with polyethylene glycol suggested as the antigenic culprit. As coronavirus disease 2019 (COVID-19) mRNA vaccines contain polyethylene glycol, the safety of administration of these vaccines to patients with prior PEGAsp hypersensitivity has been questioned. Between December 21, 2020 and March 3, 2022, 66 patients with acute leukemia and PEGAsp allergy received COVID-19 vaccination. No patients (0/66 0%, 95% CI: 0%-5.4%) experienced an allergic reaction to the vaccine. COVID-19 mRNA vaccination appears to be safe in pediatric and young adult patients with acute lymphoblastic leukemia with PEGAsp allergy.

Published
2024
Full Text
View/download PDF

44. Phase II Trial of Inotuzumab Ozogamicin in Children and Adolescents With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: Children's Oncology Group Protocol AALL1621

Author

O'Brien, Maureen M., primary, Ji, Lingyun, additional, Shah, Nirali N., additional, Rheingold, Susan R., additional, Bhojwani, Deepa, additional, Yuan, Constance M., additional, Xu, Xinxin, additional, Yi, Joanna S., additional, Harris, Andrew C., additional, Brown, Patrick A., additional, Borowitz, Michael J., additional, Militano, Olga, additional, Kairalla, John, additional, Devidas, Meenakshi, additional, Raetz, Elizabeth A., additional, Gore, Lia, additional, and Loh, Mignon L., additional

Published
2022
Full Text
View/download PDF

45. Blinatumomab Nonresponse and High-Disease Burden Are Associated With Inferior Outcomes After CD19-CAR for B-ALL

Author

Myers, Regina M., primary, Taraseviciute, Agne, additional, Steinberg, Seth M., additional, Lamble, Adam J., additional, Sheppard, Jennifer, additional, Yates, Bonnie, additional, Kovach, Alexandra E., additional, Wood, Brent, additional, Borowitz, Michael J., additional, Stetler-Stevenson, Maryalice, additional, Yuan, Constance M., additional, Pillai, Vinodh, additional, Foley, Toni, additional, Chung, Perry, additional, Chen, Lee, additional, Lee, Daniel W., additional, Annesley, Colleen, additional, DiNofia, Amanda, additional, Grupp, Stephan A., additional, John, Samuel, additional, Bhojwani, Deepa, additional, Brown, Patrick A., additional, Laetsch, Theodore W., additional, Gore, Lia, additional, Gardner, Rebecca A., additional, Rheingold, Susan R., additional, Pulsipher, Michael A., additional, and Shah, Nirali N., additional

Published
2022
Full Text
View/download PDF

46. Modulation of CD22 Protein Expression in Childhood Leukemia by Pervasive Splicing Aberrations: Implications for CD22-Directed Immunotherapies

Author

Zheng, Sisi, primary, Gillespie, Elisabeth, additional, Naqvi, Ammar S., additional, Hayer, Katharina E., additional, Ang, Zhiwei, additional, Torres-Diz, Manuel, additional, Quesnel-Vallières, Mathieu, additional, Hottman, David A., additional, Bagashev, Asen, additional, Chukinas, John, additional, Schmidt, Carolin, additional, Asnani, Mukta, additional, Shraim, Rawan, additional, Taylor, Deanne M., additional, Rheingold, Susan R., additional, O'Brien, Maureen M., additional, Singh, Nathan, additional, Lynch, Kristen W., additional, Ruella, Marco, additional, Barash, Yoseph, additional, Tasian, Sarah K., additional, and Thomas-Tikhonenko, Andrei, additional

Published
2022
Full Text
View/download PDF

48. List of Contributors

Author

Abdel-Azim, Hisham, primary, Acharya, Suchitra S., additional, Agrawal, Anurag K., additional, Arceci, Robert J., additional, Atlas, Mark P., additional, Bagatell, Rochelle, additional, Bernthal, Nicholas, additional, Bhatla, Teena, additional, Blanc, Lionel, additional, Bonilla, Mary Ann, additional, Bussel, James B., additional, Carroll, William L., additional, Dome, Jeffrey S., additional, Van Dyne, Elizabeth A., additional, Elghetany, Tarek M., additional, Federman, Noah, additional, Fein Levy, Carolyn, additional, Feusner, James, additional, Fish, Jonathan D., additional, Freedman, Jason L., additional, Friedman, Debra L., additional, Hanson, Derek R., additional, Hofmann, Inga, additional, Huang, Mary S., additional, Kessel, Rachel, additional, Krystal, Julie I., additional, Kwiatkowski, Janet L., additional, Lanzkowsky, Philip., additional, Leahey, Ann, additional, Lipton, Jeffrey M., additional, Luban, Naomi L.C., additional, McGuinn, Catherine, additional, Menell, Jill S., additional, Olson, Thomas A., additional, Park, Julie R., additional, Prchal, Josef T., additional, Rapkin, Louis B., additional, Redner, Arlene, additional, Rheingold, Susan R., additional, Sahdev, Indira, additional, Sankaran, Vijay G., additional, Sarangi, Susmita N., additional, Tashi, Tsewang, additional, Teachey, David T., additional, Tippy, Meg, additional, Vlachos, Adrianna, additional, Warwick, Anne B., additional, Weinstein, Howard, additional, Wexler, Leonard H., additional, Wolfe, Lawrence C., additional, and Wong, Edward C.C., additional

Published
2016
Full Text
View/download PDF

50. Temsirolimus combined with cyclophosphamide and etoposide for pediatric patients with relapsed/refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium trial (TACL 2014-001)

Author

Tasian, Sarah K., primary, Silverman, Lewis B., additional, Whitlock, James A., additional, Sposto, Richard, additional, Loftus, Joseph P., additional, Schafer, Eric S., additional, Schultz, Kirk R., additional, Hutchinson, Raymond J., additional, Gaynon, Paul S., additional, Orgel, Etan, additional, Bateman, Caroline M., additional, Cooper, Todd M., additional, Laetsch, Theodore W., additional, Sulis, Maria Luisa, additional, Chi, Yueh-Yun, additional, Malvar, Jemily, additional, Wayne, Alan S., additional, and Rheingold, Susan R., additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results